Clinical Gastroenterology and Hepatology
Volume 7, Issue 8 , Pages 816-822, August 2009

What Makes Individuals With Gastroesophageal Reflux Disease Dissatisfied With Their Treatment?

  • Peter Bytzer

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Dr Peter Bytzer, Department of Medical Gastroenterology, Køge University Hospital, DK-4600 Køge, Denmark. fax: (45) 56-63-15-52

published online 16 March 2009.

Background & Aims

Despite the efficacy of proton pump inhibitors (PPIs) as therapeutics for patients with gastroesophageal reflux disease (GERD) in randomized controlled trials, a number of studies have shown that a proportion of patients with GERD are not satisfied with their treatment. This article reviews the possible reasons why patients are dissatisfied with the way their disease is managed.

Methods

Studies published between 1970 and 2007 were identified from PubMed, EMBASE, and the author's existing database. The 2708 publications were reviewed, and irrelevant ones were excluded. Eleven studies were found to be appropriate for use in this review.

Results

Patients who are given prescriptions for PPIs tend to be more satisfied than those given H2-receptor antagonists. Partial responders are likely to be more dissatisfied than patients whose symptoms are fully resolved. A decrease in health-related quality of life is associated with greater dissatisfaction. Patients are more likely to be satisfied if they are taken seriously by their physician and if their symptoms are investigated. They are also more likely to be satisfied if the patient-physician consultation is interactive.

Conclusions

Patient satisfaction is a complex issue that depends on many factors. Patient satisfaction can be influenced by treatment regimen, general level of well-being, the bedside manner of the physician, and the quality of patient-physician communication. Improvements in recognition of GERD can improve management of the disease as well as patient satisfaction with their care and treatment.

Abbreviations used in this paper: GERD, gastroesophageal reflux disease, H2RA, H2-receptor antagonist, HRQoL, health-related quality of life, PPI, proton pump inhibitor, QOLRAD, Quality of Life in Reflux and Dyspepsia.

 

 Conflicts of interest The author discloses the following: Peter Bytzer has received research funding from manufacturers of proton pump inhibitors (AstraZeneca, Eisai, Janssen-Cilag) and H2-receptor antagonists (Eli Lilly, GlaxoSmithKline) and has served on advisory boards, as a consultant, and on the speakers' bureau for manufacturers of antireflux medication (AstraZeneca, Eisai, Janssen-Cilag, Nycomed, Orexo, Reckitt Benckiser, Wyeth).

PII: S1542-3565(09)00215-8

doi:10.1016/j.cgh.2009.03.006

Clinical Gastroenterology and Hepatology
Volume 7, Issue 8 , Pages 816-822, August 2009